GlassScriptPhysician profile
Timothy Earl Mathis
NPI 1730185927
$3,267.18
in general payments reported to CMS, 2019-2025
29 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $325 · 2021: $912 · 2022: $440 · 2023: $336 · 2024: $509 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $450.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.10 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $319.00 | 2020-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $290.87 | 2019-2023 | Dificid, Gardasil 9, Vaxneuvance |
| Abbvie INC. | $261.75 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $241.80 | 2021-2025 | Farxiga, Airsupra |
| Amgen INC. | $227.69 | 2020-2024 | Evenity |
| Dexcom, INC. | $147.26 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $108.34 | 2021-2025 | |
| Astellas Pharma US INC | $101.52 | 2019-2020 | |
| Exact Sciences Corporation | $101.18 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $88.06 | 2019 | |
| Axsome Therapeutics, INC. | $84.99 | 2023 | Auvelity |
| Lilly USA, LLC | $81.64 | 2021-2023 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $81.22 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $53.82 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.45 | 2022 | |
| Abbott Laboratories | $38.14 | 2022-2024 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $24.20 | 2019 | |
| Itamar Medical INC | $24.17 | 2024 | Watchpatone |
| Ethicon US, LLC | $20.92 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $19.54 | 2021 | |
| Abiomed | $18.14 | 2025 | |
| Medtronic, INC. | $18.08 | 2024 | Intellis Adaptivestim |
| Hologic Sales and Service, LLC | $16.58 | 2021 | |
| Neos Therapeutics, LP | $15.59 | 2019 | |
| Amarin Pharma, INC. | $14.53 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.09 | 2024 | |
| Jazz Pharmaceuticals INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.